20/20 Biolabs Inc (NASDAQ:AIDX) Short Interest Update

20/20 Biolabs Inc (NASDAQ:AIDX) was the target of a significant drop in short interest during the month of July. As of July 31st, there was short interest totaling 153,293 shares, a drop of 38.3% from the July 15th total of 248,647 shares. Based on an average trading volume of 118,274 shares, the short-interest ratio is currently 1.3 days. Approximately 1.8% of the company’s shares are short sold.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on AIDX shares. Weiss Ratings upgraded 20/20 Biolabs from a “sell (e-)” rating to a “sell (e)” rating in a report on Monday, August 3rd. Maxim Group started coverage on shares of 20/20 Biolabs in a research report on Monday, May 11th. They set a “buy” rating and a $5.00 price target on the stock. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $5.00.

20/20 Biolabs Price Performance

Shares of AIDX traded up $0.01 during mid-day trading on Wednesday, hitting $0.53. 7,094 shares of the company’s stock were exchanged, compared to its average volume of 521,851. 20/20 Biolabs has a fifty-two week low of $0.40 and a fifty-two week high of $50.00. The company has a 50 day simple moving average of $0.56. The stock has a market cap of $6.48 million and a price-to-earnings ratio of -1.87.

20/20 Biolabs (NASDAQ:AIDX) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.26) earnings per share (EPS) for the quarter. The firm had revenue of $0.73 million for the quarter.

20/20 Biolabs Company Profile

We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026.